Background: Chronic obstructive pulmonary disease (COPD) is associated with many comorbidities, but the percentage of COPD patients who develop comorbidities has not been clearly defined. Objectives: We aimed to examine the relationship between COPD and comorbidities using information obtained from the Health Search Database (HSD) owned by the Italian College of General Practitioners (SIMG), which stores information on about 1.5% of the total Italian population served by general practitioners. Methods: We conducted a population-based retrospective study using information obtained from the HSD. The software system used codes all the diagnostic records using the 9th Revision of the International Classification of Diseases. Results: Compared to the non-COPD people, COPD patients were at increased risk for cardiovascular events [ischemic heart disease (6.9% in the general population vs. 13.6% in COPD patients), cardiac arrhythmia (6.6% in the general population vs. 15.9% in COPD patients), heart failure (2.0% in the general population vs. 7.9% in COPD patients), and other forms of heart disease (10.7% in the general population vs. 23.1% in COPD patients); with a higher impact of COPD in the elderly]; non-psychotic mental disorders, including depressive disorders (29.1% in the general population vs. 41.6% in COPD patients; with a higher impact of COPD on women aged <75 years); diabetes mellitus (10.5% in the general population vs. 18.7% in COPD patients); osteoporosis (10.8% in the general population vs. 14.8% in COPD patients), with a higher impact of COPD on women aged <75 years, and malignant pulmonary neoplasms (0.4% in the general population vs. 1.9% in COPD patients). Conclusions: Our results indicate that COPD is a risk factor for these comorbid conditions.

Keywords:
Cardiovascular events, Chronic obstructive pulmonary disease, Depression, Osteoporosis
1.
Agusti A: Chronic obstructive pulmonary disease: a systemic disease. Proc Am Thorac Soc 2006;3:478–481.
2.
Agusti AG, Noguera A, Sauleda J, Sala E, Pons J, Busquets X: Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 2003;21:347–360.
3.
Wouters EF, Creutzberg EC, Schols AM: Systemic effects in COPD. Chest 2002;121:127S–130S.
4.
de Torres JP, Cordoba-Lanus E, López-Aguilar C, Muros de Fuentes M, Montejo de Garcini A, Aguirre-Jaime A, Celli BR, Casanova C: C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. Eur Respir J 2006;27:902–907.
5.
Piehl-Aulin K, Jones I, Lindvall B, Magnuson A, Abdel-Halim SM: Increased serum inflammatory markers in the absence of clinical and skeletal muscle inflammation in patients with chronic obstructive pulmonary disease. Respiration 2009;78:191–196.
6.
Murphy CA, Blyth KG, Chaudhuri R, Lafferty J, Hothersall E, Steedman T, McSharry C, Dargie HJ, Thomson NC: Assessment of the presence of occult myocardial infarction in chronic obstructive pulmonary disease using contrast-enhanced cardiac magnetic resonance imaging. Respiration 2009;78:263–269.
7.
Gan WQ, Man SF, Senthilselvan A, Sin DD: Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004;59:574–580.
8.
Agustí A: Systemic effects of chronic obstructive pulmonary disease: what we know and what we don’t know (but should). Proc Am Thorac Soc 2007;4:522–525.
9.
van Eeden SF, Sin DD: Chronic obstructive pulmonary disease: a chronic systemic inflammatory disease. Respiration 2008;75:224–238.
10.
De Martinis M, Franceschi C, Monti D, Ginaldi L: Inflamm-ageing and lifelong antigenic load as major determinants of ageing rate and longevity. FEBS Lett 2005;579:2035–2039.
11.
Sevenoaks MJ, Stockley RA: Chronic obstructive pulmonary disease, inflammation and co-morbidity – a common inflammatory phenotype? Respir Res 2006;7:70.
12.
Fabbri LM, Luppi F, Beghé B, Rabe KF: Complex chronic comorbidities of COPD. Eur Respir J 2008;31:204–212.
13.
Fabbri LM, Rabe KF: From COPD to chronic systemic inflammatory syndrome? Lancet 2007;370:797–799.
14.
Lawrenson R, Williams T, Farmer R: Clinical information for research: the use of general practice databases. J Public Health Med 1999;21:299–304.
15.
Rodríguez-Roisin R, Soriano JB: Chronic obstructive pulmonary disease with lung cancer and/or cardiovascular disease. Proc Am Thorac Soc 2008;5:842–847.
16.
van Weel C, Schellevis FG: Comorbidity and guidelines: conflicting interests. Lancet 2006;367:550–551.
17.
World Health Organization: International Classification of Diseases. Manual of the International Statistical Classification of Diseases: Injuries and Causes of Deaths (9th revision). Geneva, World Health Organization, 1977.
18.
Soriano JB, Visick GT, Muellerova H, Payvandi N, Hansell AL: Patterns of comorbidities in newly diagnosed COPD and asthma in the primary care. Chest 2005;128:2099–2107.
19.
Hole DJ, Watt GCM, Davey-Smith G, Hart CL, Gillis CR, Hawthorne VM: Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ 1996;313:711–715.
20.
Sin DD, Man SF: Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003;107:1514–1519.
21.
Curkendall SM, DeLuise C, Jones JK, Lanes S, Stang MR, Goehring E Jr, She D: Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol 2006;16:63–70.
22.
Deyo RA, Cherkin DC, Ciol MA: Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613–619.
23.
Laurent S, Boutouyrie P, Lacolley P: Structural and genetic bases of arterial stiffness. Hypertension 2005;45:1050–1055.
24.
Roman MJ, Devereux RB, Schwartz JE, Lockshin MD, Paget SA, Davis A, Crow MK, Sammaritano L, Levine DM, Shankar BA, Moeller E, Salmon JE: Arterial stiffness in chronic inflammatory diseases. Hypertension 2005;46:194–199.
25.
Sin DD, Man SF: Chronic obstructive pulmonary disease: a novel risk factor for cardiovascular disease. Can J Physiol Pharmacol 2005;83:8–13.
26.
Buffon A, Biasucci LM, Liuzzo G, D’Onofrio G, Crea F, Maseri A: Widespread coronary inflammation in unstable angina. N Engl J Med 2002;347:5–12.
27.
Macnee W, Maclay J, McAllister D: Cardiovascular injury and repair in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008;5:824–833.
28.
Tkác J, Man SFP, Sin DD: Systemic consequences of COPD. Ther Adv Respir Dis 2007;1:47–59.
29.
Bolton CE, Ionescu AA, Shiels KM, Pettit RJ, Edwards PH, Stone MD, Nixon LS, Evans WD, Griffiths TL, Shale DJ: Associated loss of fat-free mass and bone mineral density in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;170:1286–1293.
30.
Tanko LB, Bagger YZ, Christiansen C: Low bone mineral density in the hip as a marker of advanced atherosclerosis in elderly women. Calcif Tissue Int 2003;73:15–20.
31.
Schulz E, Arfai K, Liu X, Sayre J, Gilsanz V: Aortic calcification and the risk of osteoporosis and fractures. J Clin Endocrinol Metab 2004;89:4246–4253.
32.
Cauley JA, Wu L, Wampler NS, Barnhart JM, Allison M, Chen Z, Jackson R, Robbins J: Clinical risk factors for fractures in multi-ethnic women: the Women’s Health Initiative. J Bone Miner Res 2007;22:1816–1826.
33.
Sabit R, Bolton CE, Edwards PH, Pettit RJ, Evans WD, McEniery CM, Wilkinson IB, Cockcroft JR, Shale DJ: Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:1259–1265.
34.
Biskobing DM: COPD and osteoporosis. Chest 2002;121:609–620.
35.
Li L, Brennan KJ, Gaughan JP, Ciccolella DE, Kuzma AM, Criner GJ: African Americans and men with severe COPD have a high prevalence of osteoporosis. COPD 2008;5:291–297.
36.
Jørgensen NR, Schwarz P, Holme I, Henriksen BM, Petersen LJ, Backer V: The prevalence of osteoporosis in patients with chronic obstructive pulmonary disease: a cross sectional study. Respir Med 2007;101:177–185.
37.
Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288:2709–2716.
38.
Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F, American Heart Association, National Heart, Lung, and Blood Institute: Diagnosis and management of the metabolic syndrome. Circulation 2005;112:2735–2752.
39.
van den Hooven C, Ploemacher J, Godwin M: Metabolic syndrome in a family practice population: prevalence and clinical characteristics. Can Fam Physician 2006;52:982–983.
40.
Kunik ME, Roundy K, Veazey C, Souchek J, Richardson P, Wray NP, Stanley MA: Surprisingly high prevalence of anxiety and depression in chronic breathing disorders. Chest 2005;127:1205–1211.
41.
Hill K, Geist R, Goldstein RS, Lacasse Y: Anxiety and depression in end-stage COPD. Eur Respir J 2008;31:667–677.
42.
Maurer J, Rebbapragada V, Borson S, Goldstein R, Kunik ME, Yohannes AM, Hanania NA: Anxiety and depression in COPD: current understanding, unanswered questions, and research needs. Chest 2008;134(4 suppl):43S–56S.
43.
Sichletidis L, Chloros D, Spyratos D, Chatzidimitriou N, Chatziiliadis P, Protopappas N, Charalambidou O, Pelagidou D, Zarvalis E, Patakas D: The validity of the diagnosis of chronic obstructive pulmonary disease in general practice. Prim Care Respir J 2007;16:82–88.
44.
Cazzola M, Bettoncelli G, Sessa E, Cricelli C: Primary care of the patient with chronic obstructive pulmonary disease in Italy. Respir Med 2009;103:582–588.
45.
Caramori G, Bettoncelli G, Carone M, Tosatto R, Di Blasi P, Pieretto A, Invernizzi G, Novelletto BF, Ciaccia A, Adcock IM, Papi A: Degree of control of physician-diagnosed asthma and COPD in Italy. Monaldi Arch Chest Dis 2007;67:15–22.
46.
Katz A, Soodeen RA, Bogdanovic B, De Coster C, Chateau D: Can the quality of care in family practice be measured using administrative data? Health Serv Res 2006;41:2238–2254.
47.
Filippi A, Bignamini AA, Sessa E, Samani F, Mazzaglia G: Secondary prevention of stroke in Italy: a cross-sectional survey in family practice. Stroke 2003;34:1010–1014.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.